Navigation Links
Genaera Corporation Announces Second Quarter Financial Results
Date:8/11/2008

he IL-9 antibody program. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "believe," "continue," "develop," "expect," "plan" and "potential" or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to: Genaera's history of operating losses since inception and its need for additional funds to operate its business; the costs, delays and uncertainties inherent in scientific research, drug development, clinical trials and the regulatory approval process; the risk that clinical trials for Genaera's product candidates including trodusquemine (MSI-1436) and the IL-9 antibody program may be delayed or may not be successful; the risk that Genaera may not obtain regulatory approval for its products, whether due to adequacy of the development program, the conduct of the clinical trials, changing regulatory requirements, different methods of evaluating and interpreting data, regulatory interpretations of clinical risk and benefit, or otherwise; Genaera's reliance on its collaborators, in connection with the development and commercialization of Genaera's product candidates; market acceptance of Genaera's products, if regulatory approval is achieved; competition; general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industry; and the other risks and uncertainties discussed in this announcement and in Genaera's filings with the U.S. Securities and Exchange Commission, all of which are available from the Commission in its EDGAR database at http://www.sec.gov as well as other sources. You are encouraged to read these reports. Given the uncertainties affecting development stage pharmaceutical companies, you are
'/>"/>
SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Genaera Elects New Board Member and Announces Executive Appointments
2. Genaera to Present at Biotech 2007 and BIO InvestorForum
3. Genaera Corporation Announces Third Quarter Financial Results
4. Genaera Corporation to Participate in Diabetes and Obesity Panel at RBC Capital Markets Healthcare Conference
5. Genaera Corporation Announces 2007 Financial Results
6. Genaera Corporation Announces First Quarter Financial Results
7. Genaera Corporation to Present at BIO Business Forum
8. Genaera Corporation Elects Paul K. Wotton to Board of Directors
9. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... , June 29, 2015  MiMedx Group, Inc. ... utilizing human amniotic tissue and patent-protected processes to develop ... Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental ... Parker H. "Pete" Petit, has been awarded the Lifetime ... 2015 Southeast Program. The Entrepreneur Of ...
(Date:6/29/2015)... Louis, MO (PRWEB) , ... June 29, 2015 , ... ... 15 – July 16 and for the fourth year in a row, will bring ... what changes are taking place at the intersection of data and technology. The event ...
(Date:6/29/2015)... , June 29, 2015 ... and medical information products and services, today announced the ... According to the 2014 Journal Citation Reports® (JCR) published ... Impact Factors increase from 2013 to 2014, ahead of ... occupied the top rank in 62 subject categories, up ...
(Date:6/26/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... in the management information circular dated June 1, 2015 were ... of Shareholders, held earlier today, June 26 2015. ... nominees proposed by management were elected as Directors ... next Annual Meeting of Shareholders or until their ...
Breaking Biology Technology:EY Entrepreneur Of The Year Program Recognizes Pete Petit, The Chairman & CEO of MiMedx 2StampedeCon Announces 2015 Agenda 2StampedeCon Announces 2015 Agenda 3Elsevier Announces 2014 Citation Impact Highlights 2Elsevier Announces 2014 Citation Impact Highlights 3iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 2iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 3
... Small Companies In America, UNION CITY, Calif., Oct. ... products company manufacturing point-of-care,blood chemistry analysis systems, announced today ... named "Entrepreneur of,the Year" by Forbes Magazine in its ... ranked eleventh of the "200 Best Small Companies in,America." ...
... Held by GlaxoSmithKline Since June 2006, PHILADELPHIA ... The Thomson Corporation (NYSE: TOC ; TSX: ... worldwide research and,business communities, today announced the availability ... on drugs and therapies. "Who is,Making the Biggest ...
... AURORA, ON, Oct. 15 /PRNewswire-FirstCall/ - Helix BioPharma Corp.,(TSX: ... F. McElroy,has resigned as Chairman and a director of ... had a long involvement with the Company since its,amalgamation ... "On behalf of the Company, I thank him for ...
Cached Biology Technology:Abaxis CEO Clint Severson Named 'Entrepreneur of the Year' by Forbes Magazine 2Thomson Scientific Publishes 'Who Is Making The Biggest Splash?' - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007 2Thomson Scientific Publishes 'Who Is Making The Biggest Splash?' - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007 3Helix BioPharma Chairman resigns 2
(Date:6/23/2015)... , June 23, 2015   Valencell, ... the results of a recent study that illustrates ... the wrist during activity. In a study conducted ... compared along with the Apple Watch against a ... heart rate during activity. The study demonstrated that ...
(Date:6/17/2015)... , Deutschland und GERMANTOWN, Maryland , ... ®   Produktlinie mit DNA-Tests verbessert ... N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) ... neue STR-Testkits der Produktlinie Investigator ® ... den Markt eingeführt. Die neuen Kits zur Erstellung genetischer ...
(Date:6/16/2015)... QUEBEC CITY , June 16, 2015 /CNW ... announce their partnership centralized around the incorporation of ... mobile point-of-care diagnostic laboratory, the Mo-POD™. This unprecedented ... the BIO International Conference at the ... from June 15 th to ...
Breaking Biology News(10 mins):Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3
... 2011 (Rome, Italy) -- Researchers speaking in the second ... Pathogenesis, Treatment and Prevention (IAS 2011) have today provided ... and alerted delegates to the challenges that developing countries ... antiretroviral therapy (ART) coverage. The presentations reflect the ...
... Small-scale fisheries could pose a more serious threat to ... University of Exeter, published today (19 July) in the ... shows that tens of thousands of turtles from across ... small-scale fisheries. Focusing on fisheries in Peru, the ...
... use various appendages to move across surfaces prior to ... jerky form of movement known as "twitching" motility, which ... called type IV pili, or TFP. ... a professor of bioengineering and of chemistry and biochemistry ...
Cached Biology News:Plenary speakers address challenges in the delivery of sustained antiretroviral therapy in developing countries, call for social scientists to take their place at the HIV/AIDS policy-making table, and stress the need for a long-term response to AIDS 2Plenary speakers address challenges in the delivery of sustained antiretroviral therapy in developing countries, call for social scientists to take their place at the HIV/AIDS policy-making table, and stress the need for a long-term response to AIDS 3Study shows small-scale fisheries' impact on marine life 2UCLA study shows bacteria use Batman-like grappling hooks to 'slingshot' on surfaces 2
... The Neural Stem Cell Expansion Kit - Neurosphere ... neural stem cell expansion as neurospheres in ... specially formulated N-2 Plus Media Supplement, which has ... K.K. et al . (1996) Genes & ...
DNase I (Deoxyribonuclease I) digests single- and double-stranded DNA to oligodeoxyribonucleotides. Ribonuclease activity has been reduced to non-detectable levels....
... E. coli strain containing an overproducing clone ... Reverse Transcriptase catalyzes the polymerization of DNA ... Full-length copies of large mRNAs, >10 kb, ... a much lower RNase H activity than ...
... RQ1 RNase-Free DNase is a preparation ... or double-stranded DNA to produce 3-hydroxyl ... use in applications where maintaining the ... DNase is qualified for use with ...
Biology Products: